These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2367600)

  • 1. Urinary free cortisol levels in obsessive-compulsive disorder.
    Gehris TL; Kathol RG; Black DW; Noyes R
    Psychiatry Res; 1990 May; 32(2):151-8. PubMed ID: 2367600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
    Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
    J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.
    Thorén P; Asberg M; Cronholm B; Jörnestedt L; Träskman L
    Arch Gen Psychiatry; 1980 Nov; 37(11):1281-5. PubMed ID: 7436690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.
    Fallon BA; Liebowitz MR; Campeas R; Schneier FR; Marshall R; Davies S; Goetz D; Klein DF
    Arch Gen Psychiatry; 1998 Oct; 55(10):918-24. PubMed ID: 9783563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep brain stimulation for obsessive-compulsive disorder is associated with cortisol changes.
    de Koning PP; Figee M; Endert E; Storosum JG; Fliers E; Denys D
    Psychoneuroendocrinology; 2013 Aug; 38(8):1455-9. PubMed ID: 23333254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA; L'Heureux F; Hill JL; Bihari K; Bernstein SE; Murphy DL
    J Clin Psychopharmacol; 1992 Feb; 12(1):11-8. PubMed ID: 1552034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J; Insel TR
    Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group.
    Arch Gen Psychiatry; 1991 Aug; 48(8):730-8. PubMed ID: 1883256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
    Vallejo J; Olivares J; Marcos T; Bulbena A; Menchón JM
    Br J Psychiatry; 1992 Nov; 161():665-70. PubMed ID: 1422616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
    Kim SW; Dysken MW; Pheley AM; Hoover KM
    Psychiatry Res; 1994 Feb; 51(2):203-11. PubMed ID: 8022954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Symptom Checklist-90: Obsessive-Compulsive Subscale: A reliability and validity study.
    Kim SW; Dysken MW; Kuskowski M
    Psychiatry Res; 1992 Jan; 41(1):37-44. PubMed ID: 1561287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone suppression tests in patients with obsessive-compulsive disorder.
    Lieberman JA; Kane JM; Sarantakos S; Cole K; Howard A; Borenstein M; Novacenko H; Puig-Antich J
    Am J Psychiatry; 1985 Jun; 142(6):747-51. PubMed ID: 4003598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPA axis disturbance in obsessive-compulsive disorder.
    Coryell WH; Black DW; Kelly MW; Noyes R
    Psychiatry Res; 1989 Dec; 30(3):243-51. PubMed ID: 2694203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response with clomipramine in obsessive compulsive disorder--a placebo controlled study.
    Montgomery SA; Montgomery DB; Fineberg N
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):719-27. PubMed ID: 2293252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
    McCracken JT; Hanna GL
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):581-7. PubMed ID: 16190790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.